Drugs News and Research

RSS

Protein build-up may shape cancer drug response

The way cancer-causing proteins accumulate in tumors may influence how effectively a promising new generation of medicines can remove them, a study suggests.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Catheter ablation reduces AF recurrence but not quality of life

Catheter ablation for atrial fibrillation (AF) did not significantly improve AF-related quality of life compared with a sham procedure, despite reducing AF recurrence.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Oral relaxin agonist AZD5462 improves cardiac function in heart failure patients

The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in Circulation.

30 Aug 2026

Breast cancer survivors could avoid lifelong heart medication, research suggests

Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.

30 Aug 2026

Virginia Tech virologist wins federal award to study cellular virus battles

Every time your body fights a virus, cells are making split-second decisions that determine whether an infection spreads or stops.

28 Aug 2026

Cell proliferation gene plays a distinct role in cells that no longer proliferate

In a tale of identities as divergent as "The Prince and the Pauper," a well-known cancer-causing gene also influences cells in a zombie-like state meant to prevent cancer.

28 Aug 2026

New discovery paves way for highly personalized breast cancer therapies

MYC is a common oncogene that regulates tumor growth and spread, yet no approved drugs exist to target it.

28 Aug 2026

UCSF scientists build largest molecular interaction map for autism

For more than two decades, researchers have identified hundreds of genes that increase the risk of autism spectrum disorder (ASD).

28 Aug 2026

First joint guidelines address cardiovascular events and chronic kidney disease

The first-ever European Society of Cardiology Guidelines on the management of cardiovascular disease and chronic kidney disease have been developed in collaboration with the European Renal Association.

28 Aug 2026

New guidelines simplify heart failure phenotypes into two groups

Reflecting improved understanding and treatment advances, new European Society of Cardiology (ESC) Guidelines on heart failure have been published online today in the European Heart Journal and will be presented at ESC Congress 2026 this afternoon.

28 Aug 2026

Blood-brain barrier-crossing blood pressure drugs linked to lower dementia risk

In a large Australian cohort of adults with hypertension, use of blood-brain barrier-crossing antihypertensive medications was associated with a lower risk of dementia and mortality than use of non-crossing drugs. The association was strongest for beta-blockers and angiotensin II receptor blockers, although the observational design means the findings cannot establish causality.

27 Aug 2026

Study reveals how SGLT2 inhibitors improve failing heart function

Researchers have discovered that SGLT2 inhibitors, a class of drugs originally developed to treat diabetes and now widely used for heart failure, work by activating a key enzyme that helps heart cells produce and use energy more efficiently.

27 Aug 2026

Unexpected discovery points to a possible route for childhood brain tumor treatments

When researchers at Lund University investigated how the molecule UM171 works, a molecule used to make blood stem cells multiply, they made an unexpected connection.

27 Aug 2026

Personalized nutrition promotes weight loss without counting calories

The great majority of people taking part in a study lost weight by following personalised nutritional insights, rather than going on a calorie counting or restrictive diet, reveal findings from a new study.

27 Aug 2026

CAR T-cell therapy successfully reverses severe rheumatoid arthritis

Immunotherapies such as CAR T-cell therapy are used primarily to treat cancer. In the future, these patient-specific therapies, manufactured from patients' own immune cells, could also help cure autoimmune diseases.

27 Aug 2026

Biosimilars reduce financial burden for cancer patients and insurers

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care.

27 Aug 2026

Missing doses of antihypertensive medication erase life-saving cardiovascular benefits

The true impact of missing doses of blood pressure-lowering medication will be demonstrated in a presentation at ESC Congress 2026.

27 Aug 2026

Study challenges traditional breast cancer classification methods

Breast cancer is often classified as either estrogen receptor-positive (hormone-sensitive) or not. However, a new study from Karolinska Institutet suggests that this simplified classification may overlook important biological differences between patients that could affect treatment decisions.

27 Aug 2026